<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01336322</url>
  </required_header>
  <id_info>
    <org_study_id>SITA-previousGDM</org_study_id>
    <nct_id>NCT01336322</nct_id>
  </id_info>
  <brief_title>Metformin and Sitagliptin in Women With Previous Gestational Diabetes</brief_title>
  <official_title>Effects of Treatment With Metformin and/or Sitagliptin on Beta-cell Function and Insulin Resistance in Women With Previous Gestational Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pisa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pisa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the present research is to compare the effects of treatment with metformin and
      sitagliptin, alone or in association, in women with previous gestational diabetes to evaluate
      the impact of the two drugs on beta-cell function. The study results may contribute to give a
      rational approach for future investigations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double blinded study, on 45 women with previous gestational diabetes and
      impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) to assess the effects of a
      4-month treatment with metformin and/or a dipeptidyl peptidase-4 inhibitor (sitagliptin) on
      beta-cell function and insulin resistance.

      At baseline, all women will have a standardized medical history, physical, and laboratory
      examination. Plasma glucose, insulin, pro-insulin, C-peptide, glucagon, adipokines,
      pro-inflammatory molecules, and lipid profile will be determined in fasting condition. A 75g
      OGTT will be performed after an overnight fasting and sample will be drawn at 15, 30, 60, 90
      and 120 minutes for plasma glucose, C-peptide, glucagon and GLP-1 determinations. Women with
      IFG or IGT will be recruited and undergo to a hyperglycemic clamp with arginin bolus at the
      end of the test. Then the women will be randomized in 3 treatment groups: metformin (850 mg
      bid), sitagliptin (100 mg qd)or metformin (850 mg bid) + sitagliptin (100 mg qd). After
      4-month treatment, the baseline evaluation will be repeated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Beta-cell function</measure>
    <time_frame>4 months</time_frame>
    <description>Sitagliptin and/or metformin effects on beta-cell function (ISR = Insulin Secretion Rate) evaluated by mathematical model by Mari A. (Am J Physiology 2002)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>4 months</time_frame>
    <description>Sitagliptin and/or metformin effects on insulin resistance, evaluated by clamp, HOMA-index and ISI-Method..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose control</measure>
    <time_frame>4 months</time_frame>
    <description>Sitagliptin and/or metformin effects on glucose control evaluated by OGTT and HbA1c levels.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Pre-diabetes</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metformin 850 mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sitagliptin 100 mg qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin+Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sitagliptin 100 mg qd plus Metformin 850 mg bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin 850 mg bid</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Sitagliptin 100 mg qd</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin + Metformin</intervention_name>
    <description>sitagliptin 100mg + metformin 850mg</description>
    <arm_group_label>Sitagliptin+Metformin</arm_group_label>
    <other_name>janumet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subjects aged ≥18 and ≤45 years

          -  Caucasian race

          -  History of previous gestational diabetes (in the screening) during pregnancy.

          -  Female of childbearing potential must use effective contraceptive measures for at last
             1 month prior to entry into the study and should continue to use the some
             contraceptive method during the overall study period

          -  Written informed consent obtained

        Exclusion Criteria:

          -  Patients diagnosed with type 1 insulin dependent diabetes

          -  Diagnosis of diabetes in the 75g OGTT performed at entry

          -  BMI ≤18 or ≥50 Kg/m2

          -  Chronic impaired renal function

          -  Impaired liver function as shown by transaminase levels ≥ twice above the upper normal
             range

          -  History of hypersensitivity to metformin

          -  Pregnant or breast-feeding women, or women planning to become pregnant during the
             study

          -  Failure to use adequate contraception (Women of current reproductive only)

          -  Mental condition rending the subject unable to understand the nature, scope and
             possible consequences of the study

          -  Any clinically significant major organ system disease

          -  Patients with underlying concomitant medication requiring a long-term use of drugs
             potentially acting on glucose metabolism (e.g. corticosteroids, diuretics,
             beta-adrenergic drugs or others)

          -  Treatment or likelihood of requiring treatment during the study period with drugs not
             permitted by the clinical study protocol

          -  History of drug or alcohol abuse within the last 2 years or current addiction to
             substances of abuse

          -  Any disease or condition that in the opinion of the investigator may interfere with
             the completion of the study

          -  Subjects unlikely to comply with the protocol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Del Prato, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pisa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefano Del Prato, MD</last_name>
    <phone>+39 050 995103</phone>
    <email>stefano.delprato@med.unipi.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alessandra Bertolotto, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Endocrinology and Metabolism, University of Pisa</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Del Prato, MD</last_name>
      <phone>+39 050 995103</phone>
      <email>stefano.delprato@med.unipi.it</email>
    </contact>
    <investigator>
      <last_name>Graziano Di Cianni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2011</study_first_submitted>
  <study_first_submitted_qc>April 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2011</study_first_posted>
  <last_update_submitted>January 15, 2018</last_update_submitted>
  <last_update_submitted_qc>January 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pisa</investigator_affiliation>
    <investigator_full_name>Prof. Stefano Del Prato</investigator_full_name>
    <investigator_title>Clinical Resercher</investigator_title>
  </responsible_party>
  <keyword>beta-cell function</keyword>
  <keyword>insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

